Your browser doesn't support javascript.
loading
Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada, Makiko; Inoue, Shin-Ichi; Sugiyama, Daisuke; Nishiya, Yumi; Ishizuka, Tomoko; Watanabe, Akiko; Watanabe, Kengo; Yamashita, Shinji; Watanabe, Nobuaki.
  • Yamada M; Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (M.Y., S.I., D.S., Y.N., T.I., A.W., K.W., N.W.) and Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan (S.Y.) yamada.makiko.jr@daiichisankyo.co.jp.
  • Inoue SI; Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (M.Y., S.I., D.S., Y.N., T.I., A.W., K.W., N.W.) and Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan (S.Y.).
  • Sugiyama D; Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (M.Y., S.I., D.S., Y.N., T.I., A.W., K.W., N.W.) and Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan (S.Y.).
  • Nishiya Y; Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (M.Y., S.I., D.S., Y.N., T.I., A.W., K.W., N.W.) and Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan (S.Y.).
  • Ishizuka T; Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (M.Y., S.I., D.S., Y.N., T.I., A.W., K.W., N.W.) and Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan (S.Y.).
  • Watanabe A; Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (M.Y., S.I., D.S., Y.N., T.I., A.W., K.W., N.W.) and Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan (S.Y.).
  • Watanabe K; Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (M.Y., S.I., D.S., Y.N., T.I., A.W., K.W., N.W.) and Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan (S.Y.).
  • Yamashita S; Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (M.Y., S.I., D.S., Y.N., T.I., A.W., K.W., N.W.) and Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan (S.Y.).
  • Watanabe N; Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (M.Y., S.I., D.S., Y.N., T.I., A.W., K.W., N.W.) and Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan (S.Y.).
Drug Metab Dispos ; 48(4): 288-296, 2020 04.
Article en En | MEDLINE | ID: mdl-31996361
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Midazolam / Citocromo P-450 CYP3A / Inhibidores del Citocromo P-450 CYP3A / Mucosa Intestinal / Modelos Biológicos Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Midazolam / Citocromo P-450 CYP3A / Inhibidores del Citocromo P-450 CYP3A / Mucosa Intestinal / Modelos Biológicos Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article